|
2004/OB/20
|
OXFORD
BIOMEDICA LICENSES RETROVIRAL EX VIVO GENE DELIVERY TECHNOLOGY
TO MOLMED SPA
Oxford
BioMedica (LSE: OXB) and MolMed SpA (Milan, Italy) today
announced
a licence agreement for Oxford BioMedica’s
retroviral ex vivo gene delivery technology. The agreement
provides MolMed with rights to utilise this technology in
the development of MolMed’s product pipeline. Under
the agreement, Oxford BioMedica receives an upfront licence
fee and annual maintenance payments. In addition, Oxford
BioMedica will receive payments on the achievement of clinical
and regulatory milestones by MolMed and product royalties.
Further financial details were not disclosed.
The retroviral
ex vivo gene delivery technology combines Oxford BioMedica’s
technology with some of the gene therapy technology acquired
from Chiron Corporation in June
this year.
Oxford
BioMedica’s CEO, Professor Alan Kingsman, said: "We
are delighted to welcome MolMed to the list of Oxford BioMedica’s
technology licensees. This agreement provides further evidence
of the breadth and strength of our proprietary gene delivery
technology."
-
ends - |
Return to the News
| Notes
| 1. |
Oxford
BioMedica plc |
|
Oxford
BioMedica (LSE: OXB) is a biopharmaceutical
company specialising in the development
of novel gene-based therapeutics with
a focus on the areas of oncology and
neurotherapy. The Company was established
in 1995 as a spin out from Oxford University,
and is listed on the London Stock Exchange.
In
addition to its technical expertise in
gene delivery, Oxford BioMedica has
in-house clinical, regulatory and manufacturing
know-how. The development pipeline includes
two novel anti-cancer products in clinical
trials; two neurotherapy products in advanced
preclinical development for Parkinson’s
disease and retinopathy; and three further
preclinical neurotherapy products. The
Company is underpinned by an extensive
preclinical and research portfolio and
over 80 patent families, which represents
one of the broadest patent estates in the
field.
The
Company has a staff of approx. 65 split
between its main facilities in Oxford
and its wholly owned subsidiary, BioMedica
Inc, in San Diego, California. Oxford BioMedica
has corporate collaborations with Wyeth,
Intervet, Merck & Co, Amersham, Viragen
and Kiadis.
|
| 2. |
MolMed
SpA |
| |
MolMed is a biotech company focused on the
development of innovative therapies for
the treatment of cancer and AIDS. The
company is based in Milan (Italy) within
the premier Italian biomedical research
institute, the San Raffaele Biomedical
Science Park. MolMed has a diversified
and strong pipeline including two gene
therapy products against cancer and AIDS
and a cancer vaccination approach, all
in phase I/II clinical trials and based
on the company’s core competences
in ex vivo cell manipulation and genetic
modification of T lymphocytes and haematopoietic
stem cells. Furthermore, MolMed is developing
vascular targeting agents as new anti-cancer
strategy. MolMed has completed preclinical
validation of the lead candidate and
will start a phase I clinical trial in
the second half of 2004. MolMed’s
products are protected by a strong intellectual
property of 44 patent families which
the company either owns or which it has
licensed with exclusive or non-exclusive
rights.
Further information is available at http://www.molmed.com/
|
| |
| For
further information please contact:
|
|
|
Oxford BioMedica plc
Professor Alan
Kingsman, Chief Executive |
Tel: +44 (0)1865 783 000 |
| City/Financial
Enquiries
Lisa
Baderoon/Mark
Court/Mary-Jane
Johnson
Buchanan Communications |
Tel: +44 (0)20 7466 5000
|
Scientific/Trade
Press Enquiries
Sue
Charles, Katja
Stout, Ashley
Lilly
College Hill - Life Sciences |
Tel:
+44 (0)20 7886 8150 |
|
|
|
|
|
Top
of page
Website by College Hill - Life Sciences
|
| |
|
|
